Galectin Therapeutics Inc. (GALT)
- GlobeNewswire
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
NORCROSS, Ga., May 23, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the H.C. Wainwright Global Investment Conference being held from May 23-26, 2022 and at the 5th Global NASH Congress in London, UK on May 26-27, 2022. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will make a corporate presentation at the Wainwright Global Investment Con
- GlobeNewswire
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2022. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov. Dr. Pol Boudes, Chief Medical Officer, stated: “As we
- Zacks
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
